Stella Pharma Past Earnings Performance
Past criteria checks 0/6
Stella Pharma has been growing earnings at an average annual rate of 3.5%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 33.9% per year.
Key information
3.5%
Earnings growth rate
26.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 33.9% |
| Return on equity | -32.1% |
| Net Margin | -283.6% |
| Next Earnings Update | 31 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Stella Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 269 | -763 | 977 | 0 |
| 31 Dec 23 | 254 | -764 | 592 | 374 |
| 30 Sep 23 | 290 | -739 | 597 | 374 |
| 30 Jun 23 | 244 | -747 | 606 | 374 |
| 31 Mar 23 | 229 | -778 | 625 | 374 |
| 31 Dec 22 | 191 | -690 | 624 | 255 |
| 30 Sep 22 | 123 | -703 | 578 | 255 |
| 30 Jun 22 | 139 | -741 | 601 | 255 |
| 31 Mar 22 | 100 | -767 | 555 | 255 |
| 31 Dec 21 | 134 | -715 | 493 | 307 |
| 31 Mar 21 | 205 | -659 | 539 | 307 |
| 31 Mar 20 | 0 | -962 | 951 | 0 |
Quality Earnings: 4888 is currently unprofitable.
Growing Profit Margin: 4888 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4888 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare 4888's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4888 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.3%).
Return on Equity
High ROE: 4888 has a negative Return on Equity (-32.11%), as it is currently unprofitable.